In the English version of today's Orion Corporation Stock Exchange Release concerning Disclosure under Chapter 2, Section 10 of the Securities Markets Act, the words: "and related voting rights" were mistakenly included in the first sentence. The correct wording of the sentence is: "Orion Corporation (business code 1999212-6) has received a disclosure under Chapter 2, Section 9 of the Securities Markets Act, according to which the total number of Orion B shares under management of The Capital Group Companies, Inc., exceeded on 3 September 2012 the one twentieth (1/20) threshold of the total number of Orion Corporation shares."
In the Finnish version of the Stock Exchange Release the sentence is correct.The correct English version of the Stock Exchange Release is in its entirety the following:
Disclosure Under Chapter 2 Section 10
Orion Corporation (business code 1999212-6) has received a disclosure under Chapter 2, Section 9 of the Securities Markets Act, according to which the total number of Orion B shares under management of The Capital Group Companies, Inc., exceeded on 3 September 2012 the one twentieth (1/20) threshold of the total number of Orion Corporation shares.
Previously, Capital Research and Management Company (CRMC) and Capital Group International, Inc. (CGII), subsidiaries of The Capital Group Companies, Inc., have reported their holdings separately based on an exemption granted by the Finnish Financial Supervision Authority on 12 September 2007 (J No 13/230/2007). As a result of the corporate re-organization effective 1 September 2012, the exemption no longer applies to CRMC and CGII. Consequently, The Capital Group Companies, Inc. now reports its holdings in aggregate.
The holdings managed by The Capital Group Companies, Inc., according to the disclosure:
|Share type||Number of shares|| Percent (%) of |
| Percent (%) |
| B share |
The taxpayer I.D. advised by The Capital Group Companies, Inc: 86-0206507.
Additional information about the company: www.capgroup.com.
Orion Corporation's share capital comprises 141,257,828 shares, of which 44,493,218 are A shares and 96,764,610 are B shares. Each A share entitles its holder to twenty (20) votes and each B share to one (1) vote. Thus, the total number of votes is 986,628,970.
|Timo Lappalainen |
President and CEO
|Olli Huotari |
SVP, Corporate Functions
Olli Huotari, SVP, Corporate Functions, phone +358 50 966 3054
Orionintie 1A, FI-02200 Espoo
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.